Trastuzumab deruxtecan positive CHMP
14 December 2020 07:05 GMT Trastuzumab deruxtecan recommended for approval in theEU by CHMP for HER2-positive metastatic breast cancer Recommendation based on positive results from the DESTINY-Breast01 trial,which showed durable responses in patients with previously treated disease AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s trastuzumab deruxtecan has been recommended for conditional marketing authorisation in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have